Drug Profile
Research programme: psychiatric disorder therapies - Chakra Biotech/Tikvah Therapeutics
Alternative Names: CB 010002; CB 020001; CB 030004; CB-030006Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Chakra Biotech
- Developer Chakra Biotech; Tikvah Therapeutics
- Class
- Mechanism of Action Adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 5-HT2 receptor modulators; Serotonin 5-HT2A receptor modulators; Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bipolar disorders; Psychiatric disorders; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bipolar-disorders in Singapore
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bipolar-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psychiatric-disorders in Singapore